Evidence map›Paper›PMID 42076879›Full record

ArticleJournal of medicinal chemistry2026

Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders.

Daniel T Webb, Katherine L Jones, Natsuko Macabuag, Ruzica Bago, Joshua Betts, Sumit Bhattacharyya, Steve Clifton, Ryan A J Tinson, Chigozie Achara, Simon Gilbert and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Daniel T WebbDepartment of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom.
Katherine L JonesDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.ORCID 0000-0003-4853-8283
Natsuko MacabuagDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Ruzica BagoDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Joshua BettsDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Sumit BhattacharyyaDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Steve CliftonDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Ryan A J TinsonDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Chigozie AcharaDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Simon GilbertDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
Stefanie HowellStructural Genomics Consortium (SGC) and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
David H DrewryStructural Genomics Consortium (SGC) and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-5973-5798
Rebecca RogersDivision of Molecular Pathology and Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom.
Chris JonesDivision of Molecular Pathology and Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom.
Kyle R FergusonCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom.
Alex N BullockCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom.ORCID 0000-0001-6757-0436
David M LindsayDepartment of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom.ORCID 0000-0003-4498-5094
William J KerrDepartment of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom.ORCID 0000-0002-1332-785X
William EsmieuDiscovery from Charles River, Charles River, Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activin receptor-like kinase 2 (ACVR1/ALK2) regulates bone morphogenetic protein signaling, and ALK2 modulation has been identified as a promising therapeutic strategy for conditions including fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG), and glioblastoma. Herein, we report on the development of first-in-class ALK2 degraders, including

Indexed as

Activin Receptors, Type IProtein Kinase InhibitorsAnimalsHumansProteolysisStructure-Activity RelationshipActivin Receptors, Type IACVR1 protein, humanProtein Kinase Inhibitors

Identifiers

PMID42076879
PMCPMC13181787

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.